| Schedule of Segment Information |
The following table is a summary of segment information for the three and six months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Late-stage development |
|
$ |
25,593 |
|
|
$ |
27,115 |
|
|
$ |
53,695 |
|
|
$ |
55,212 |
|
Early-stage, preclinical and discovery programs |
|
|
11,791 |
|
|
|
10,039 |
|
|
|
25,766 |
|
|
|
19,817 |
|
R&D personnel related |
|
|
17,600 |
|
|
|
14,568 |
|
|
|
35,647 |
|
|
|
29,442 |
|
Research and development software, facilities and other strategic support |
|
|
6,537 |
|
|
|
4,907 |
|
|
|
12,271 |
|
|
|
9,332 |
|
Other operational infrastructure and advisory support |
|
|
23,269 |
|
|
|
8,582 |
|
|
|
43,484 |
|
|
|
15,693 |
|
Stock-based compensation expense |
|
|
17,107 |
|
|
|
9,716 |
|
|
|
34,015 |
|
|
|
19,724 |
|
Depreciation expense |
|
|
741 |
|
|
|
655 |
|
|
|
1,367 |
|
|
|
1,295 |
|
Interest income |
|
|
(7,461 |
) |
|
|
(2,373 |
) |
|
|
(15,069 |
) |
|
|
(5,325 |
) |
Interest expense |
|
|
1,217 |
|
|
|
314 |
|
|
|
2,430 |
|
|
|
314 |
|
Other expense (income), net |
|
|
11 |
|
|
|
6 |
|
|
|
151 |
|
|
|
11 |
|
Segment net loss and consolidated net loss |
|
$ |
96,405 |
|
|
$ |
73,529 |
|
|
$ |
193,757 |
|
|
$ |
145,515 |
|
|